Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (61-70 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
The Journal of Antimicrobial Chemotherapy|October 9, 2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsLouisa Pollock, Laura Else, Goenke Poerksen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapiesDaryl Hodge, Fiona Marra, Catia Marzolini, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intakeEmilie Elliot, Alieu Amara, Akil Jackson, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
AIDS (London, England)|May 31, 2013
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical DiseasesKay Seden, Saye Khoo, David Back, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjectsBorja Mora-Peris, Adam Croucher, Laura J Else, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteersBorja Mora-Peris, Laura Else, David Goldmeier, et al.
Pageof 15

Showing results (61-70 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
The Journal of Antimicrobial Chemotherapy|October 9, 2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsLouisa Pollock, Laura Else, Goenke Poerksen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapiesDaryl Hodge, Fiona Marra, Catia Marzolini, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intakeEmilie Elliot, Alieu Amara, Akil Jackson, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
AIDS (London, England)|May 31, 2013
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical DiseasesKay Seden, Saye Khoo, David Back, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjectsBorja Mora-Peris, Adam Croucher, Laura J Else, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteersBorja Mora-Peris, Laura Else, David Goldmeier, et al.
Pageof 15